BioRem
CVE:BRMBioRem Inc., a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs. The company also provides multi-stage systems to remove odors from various municipal/urban wastewater treatment processes; biogas desulfurization systems; dry scrubber adsorption systems; and cannabis odor control systems. In addition, it offers biological processes and testing services; media sampling and analysis; system review and inspections; and media replacements and spare parts. The company operates in Canada, the United States, China, and internationally. BioRem Inc. was founded in 1990 and is headquartered in Puslinch, Canada.
iShares MSCI Singapore ETF
NYSEARCA:EWSiShares MSCI Singapore ETF, formerly iShares MSCI Singapore Index Fund (the Fund), is an exchange traded fund (ETF). The Funds seeks investment results that correspond to the price and yield performance of the MSCI Singapore Index (the Underlying Index). The Underlying Index consists of stocks traded primarily on the Singapore Stock Exchange. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund's investment advisor is BlackRock Fund Advisors (BFA).
Protalix BioTherapeutics
NYSE:PLXProtalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
(TMG)
NYSE:TMGTaylor & Martin Group, Inc. provide marketplaces and value-added solutions for the liquidation of pre-owned capital assets, excess inventory and returned consumer goods. The Company's platform, which it refers to as its TMG Complete Solution, offers a range of services, including pre-owned capital assets, such as commercial trucks and trailers, agricultural, construction and industrial equipment, and excess inventory and returned consumer goods, such as footwear, apparel and accessories, electronics and general merchandise. It served these targeted markets through its two operating divisions: TMG Auction Services and TMG Reverse Logistics.